Mark Moasser

Mark Moasser is a Professor at the University of California San Francisco (UCSF) School of Medicine. He leads a translational cancer research program focused on tyrosine kinase signaling in epithelial cancers, particularly HER2-amplified cancers, bridging laboratory discoveries with clinical trials. His dual expertise in Medical Oncology and scientific research enables him to pursue clinically relevant questions while maintaining a strong foundation in basic science.

• Education: B.A. from University of Pennsylvania (1984), M.D. from Tufts University School of Medicine (1988), Residency in Internal Medicine at New York Hospital-Cornell Medical Center (1988-1991), Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center (1991-1996).

His research spans structural biology, cell signaling, tumor biology, and clinical trials, with a focus on HER2-HER3 signaling in breast and other cancers. Collaborations include structural biologists (John Kuriyan, Natalia Jura) and small-molecule discovery groups (Jim Wells, Michelle Arkin).

Moasser has secured significant funding from NIH, Susan G. Komen Foundation, California Breast Cancer Research Program, and AACR-BCRF for projects like Understanding resistance in the HER2-HER3 tumor drive and Development of first-in-class HER3 inhibitors.

• Scientific Awards:
  • Phi Beta Kappa (1984)
  • Clinical and Molecular Cancer Research Training Fellowship (1992-1993)
  • ASCO Young Investigator Award (declined, 1994)
  • Dana Fellowship (1993-1995)
  • Clinical Scholars Award (1993-1995)
  • Ethel Abbott Fellowship (1995-1996)
  • Byrne Fund Award (1997-1999)
  • ASCO Career Development Award (1997-2000)
  • American Cancer Society Research Scholar (2002-2006)
  • Susan Komen Award (2005-2006)
  • California Breast Cancer Research Program Award (2008)
  • Elected to American Society for Clinical Investigation